Skip to main
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics is expected to continue its positive momentum in the coming years as it progresses towards the approval and launch of its flagship product candidate, nomlabofusp, for the treatment of Friedreich's ataxia. In addition, the company's novel cell penetrating peptide technology platform has the potential to address other rare diseases, providing a promising pipeline for future growth. While the current cash runway may pose some constraints, the company may benefit from potential monetization opportunities of a Priority Review Voucher upon approval. This, along with a potential secondary offering, could help address the need for additional funding to support the regulatory process. Overall, the potential of nomlabofusp to become a disease-modifying treatment for FA patients, coupled with the company's strong technological foundation, makes Larimar Therapeutics an attractive investment opportunity for long-term growth.

Bears say

Larimar Therapeutics is a clinical-stage biotechnology company with a high-risk, single product development strategy for their lead program, nomlabofusp, which targets a niche market for Friedreich's ataxia. Despite some promising clinical data, there are significant risks related to remaining regulatory approvals, manufacturing, and possible equity dilution which impact the company's valuation of $1.19B and $1.33B in total enterprise and firm value, respectively. Additionally, the company's reliance on external funding to advance their pipeline may lead to delays or termination of development campaigns.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.